range of sample prep, synthesis and bioanalytical tools for biotherapeutics discovery, development and bioprocessing. With an installed base of more than 1,000 instruments in biopharmaceutical and related markets, coupled with double digit revenue growth and ebitda positive operations, the combined company is in a strong position to continue delivering innovative products to its customers. The merger with Gyros AB further strengthens our R D and manufacturing infrastructure to enable faster development of new biotherapeutics discovery platforms and consumables. Gyros Protein Technologies will be led by Dan Calvo as CEO (currently CEO of Gyros AB) and Erik Wiberg as CFO (currently CFO of Protein Technologies). Calvo commented: Gyros Protein Technologies will build upon the exceptional customer service capabilities and quality culture of Gyros and Protein Technologies. Occupying a top tier market position in several key application areas, most notably bioprocess, and with the target markets representing an opportunity approaching 1 billion worldwide, we are very excited at the prospects this merger offers. The combined company has a clear business vision, strong and profitable historical growth, and an aggressive acquisition strategy going forward. Patteson added: The fields of proteins and peptides have merged, and hence so have we, creating a biotherapeutics discovery-to-production offering ideally positioning us for future expansion. More information on AP6 can be found. Ends, notes to editors. About AP6, the sixth Swedish National Pension Fund (AP6) is a long-term and active investor in private equity.
With a large and growing installed base of instruments in the biopharmaceutical industry, as well as with CRO and CMO partners, Gyros Protein Technologies is leading its field in several key application areas in biotherapeutics, from research through Phase 4 clinical development and particularly. Direct investments are made primarily in conjunction with other financial investors, who share our values and have a long-term investment horizon. Gyros launched Gyrolab xPlore, an automated, nanoliter-scale, single CD immunoassay system, while Protein Technologies introduced the Prelude X which incorporates novel, efficient heating and UV monitoring technology for economical, rapid synthesis of even the most difficult peptides.
Media markt uppsala öppettider midsommar
Folktandvården liljefors torg uppsala
Sfi linneskolan uppsala
Formed in March 2016 by the merger of Gyros AB and Protein Technologies, Inc., the Company combines Gyros microfluidics, systems development and immunoassay expertise with Protein Technologies deep knowledge in developing and manufacturing instruments for peptide synthesis. Our combined service and sales organization will have expanded geographic presence, enabling Gyros Protein Technologies to provide even stronger levels of support to its global customers. The merger is expected to be completed within the next 30 days and is subject to certain closing conditions. Cosper said: Protein Technologies has developed deep partnerships with its customers to develop innovative synthesis platforms for peptide science. Current majority shareholders of both Gyros AB and Protein Technologies, Inc., which are the AP6 and Ampersand Capital Partners respectively, become the major shareholders in Gyros Protein Technologies. Both Gyros and Protein Technologies introduced new platforms in 2015. Additional information about Ampersand is available. About Ampersand Capital Partners, ampersand Capital Partners is a middle market private equity firm with a focus on growth equity investments in the healthcare sector. The Company has a strong base for further organic growth, supplemented with future M A activity, which will be a focus of the Companys executives, shareholders and board of directors. The Company holds a high growth, high margin product portfolio, including 50 in recurring aftermarket consumables and service revenue, coupled with a reputation for exceptional customer service and support.